Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rocket Pharmaceuticals (RCKT) Long-Term Investments (2018 - 2023)

Rocket Pharmaceuticals (RCKT) has disclosed Long-Term Investments for 3 consecutive years, with $34.3 million as the latest value for Q4 2023.

  • Quarterly Long-Term Investments fell 20.7% to $34.3 million in Q4 2023 from the year-ago period, while the trailing twelve-month figure was $34.3 million through Dec 2023, down 20.7% year-over-year, with the annual reading at $34.3 million for FY2023, 20.7% down from the prior year.
  • Long-Term Investments hit $34.3 million in Q4 2023 for Rocket Pharmaceuticals, up from $29.0 million in the prior quarter.
  • In the past five years, Long-Term Investments ranged from a high of $43.3 million in Q4 2022 to a low of $29.0 million in Q1 2023.